APPA Peptide Biosynthesis via Engineered Gene Operons
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The synthesis of (Z)-L-2-amino-5-phosphono-3-pentenoic acid (APPA)-containing peptides, such as rhizocticins and plumbemycins, is challenging and impractical for commercial production due to the difficulty in producing modified APPA-containing peptides from their native bacteria, limiting their viability as anti-fungal and anti-bacterial agents.
Innovation Solution
Identification and description of gene operons for the production of APPA-containing peptides, including the rhizocticin and plumbemycin gene clusters, allowing for the biosynthetic preparation of these peptides and the modification of N-terminal amino acids to create analogs with desired specificity through genetic engineering and nucleic acid sequences with high sequence identity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If traditional chemical synthesis methods are used to produce APPA-containing peptides, then the peptides can be obtained, but the synthesis is very challenging and commercially impractical
Solution Approach 1:
The patent replaces traditional chemical synthesis methods with a biological production system using engineered bacteria. The bacteria naturally produce APPA-containing peptides through metabolic pathways, substituting chemical synthesis machinery with biological production machinery. This is achieved by introducing or modifying genes encoding enzymes involved in APPA biosynthesis into bacterial hosts, allowing them to produce the peptides commercially viable quantities through fermentation processes.
2Ease of manufacture
If modified APPA-containing peptides are produced from native bacteria, then commercial production becomes feasible, but the ability to modify N-terminal amino acids is limited
Solution Approach 1:
The patent employs dynamic genetic engineering approaches where the bacterial production system can be reconfigured to produce different peptide variants. By modifying the genes encoding the N-terminal amino acid sequences or introducing alternative amino acid biosynthesis pathways, the system can be dynamically adjusted to produce various modified peptides while maintaining commercial production feasibility through the same engineered bacterial platform.
Data Source
AI summary
The disclosure of the present application provides polypeptide sequences and nucleotide sequences coding for the polypeptide sequences of proteins used in the production of APPA-containing peptides. In at least one embodiment of the present disclosure, an isolated nucleic acid is disclosed which comprises a nucleotide sequence encoding a polypeptide having a sequence identity of 60 percent or greater to an amino acid sequence selected from the group consisting of SEQ ID NOS: 2-13, and 15-23.